Literature DB >> 28483763

Effect of a near-universal hospitalization-based prophylaxis regimen on annual number of venous thromboembolism events in the US.

John A Heit1,2,3, Daniel J Crusan4, Aneel A Ashrani2, Tanya M Petterson4, Kent R Bailey4.   

Abstract

The annual number of US venous thromboembolism (VTE) events, the number of potentially preventable events, and the effect of hospitalization-based prophylaxis are uncertain. We estimated VTE attack (incident plus recurrent VTE) rates and the total annual number of US VTE events related and unrelated to hospitalization using Rochester Epidemiology Project resources to identify all Olmsted County, Minnesota, residents with incident or recurrent VTE over the 6-year period 2005-2010. The average annual VTE attack rates related and unrelated to hospitalization were 282 and 8 per 10 000 person-years, respectively. The estimated average number of US VTE events was 495 669 per year (48% unrelated to hospitalization). Among Olmsted County residents hospitalized at a Mayo Clinic hospital from 2005 to 2010, the proportion of patients receiving VTE prophylaxis or with an indication that prophylaxis was unnecessary increased from ∼40% in 2005 to ∼90% by 2010. The annual age- and sex-adjusted hospitalization-related (in-hospital) VTE attack rates from 2005 to 2010 ranged from 251 to 306 (1155 to 1751) per 10 000 person-years (bed-years) and did not change significantly. The median durations of hospitalization and in-hospital prophylaxis were 3 days and 70 hours, respectively. A total of 75% of VTE events occurred after hospital discharge, with a 19.5-day median time to VTE. Additional efforts are needed to identify the individual inpatient and outpatient at high risk for incident and recurrent VTE and target (longer duration) primary and secondary prophylaxis to high-risk individuals who would benefit most.
© 2017 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28483763      PMCID: PMC5510788          DOI: 10.1182/blood-2016-12-758995

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

1.  Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.

Authors:  Samuel Z Goldhaber; Alain Leizorovicz; Ajay K Kakkar; Sylvia K Haas; Geno Merli; Robert M Knabb; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

2.  Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project.

Authors:  Jennifer L St Sauver; Brandon R Grossardt; Cynthia L Leibson; Barbara P Yawn; L Joseph Melton; Walter A Rocca
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

3.  Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial.

Authors:  Alexander T Cohen; Bruce L Davidson; Alexander S Gallus; Michael R Lassen; Martin H Prins; Witold Tomkowski; Alexander G G Turpie; Jan F M Egberts; Anthonie W A Lensing
Journal:  BMJ       Date:  2006-01-26

4.  Reasons for the persistent incidence of venous thromboembolism.

Authors:  John A Heit; Aneel Ashrani; Daniel J Crusan; Robert D McBane; Tanya M Petterson; Kent R Bailey
Journal:  Thromb Haemost       Date:  2016-12-15       Impact factor: 5.249

5.  Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study.

Authors:  J A Heit; D N Mohr; M D Silverstein; T M Petterson; W M O'Fallon; L J Melton
Journal:  Arch Intern Med       Date:  2000-03-27

6.  Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study.

Authors:  Cheng E Chee; Aneel A Ashrani; Randolph S Marks; Tanya M Petterson; Kent R Bailey; L Joseph Melton; John A Heit
Journal:  Blood       Date:  2014-04-29       Impact factor: 22.113

7.  Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester epidemiology project.

Authors:  Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Walter A Rocca
Journal:  Am J Epidemiol       Date:  2011-03-23       Impact factor: 4.897

8.  Venous thromboembolism in adult hospitalizations - United States, 2007-2009.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2012-06-08       Impact factor: 17.586

9.  Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009).

Authors:  Wei Huang; Robert J Goldberg; Frederick A Anderson; Catarina I Kiefe; Frederick A Spencer
Journal:  Am J Med       Date:  2014-05-06       Impact factor: 4.965

10.  Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients.

Authors:  Alexander T Cohen; Robert A Harrington; Samuel Z Goldhaber; Russell D Hull; Brian L Wiens; Alex Gold; Adrian F Hernandez; C Michael Gibson
Journal:  N Engl J Med       Date:  2016-05-27       Impact factor: 91.245

View more
  25 in total

1.  Extended thromboprophylaxis for medically ill patients with cancer: a systemic review and meta-analysis.

Authors:  Soravis Osataphan; Rushad Patell; Thita Chiasakul; Alok A Khorana; Jeffrey I Zwicker
Journal:  Blood Adv       Date:  2021-04-27

2.  Establishment of Prediction Models for Venous Thromboembolism in Non-Oncological Urological Inpatients - A Single-Center Experience.

Authors:  Kaixuan Li; Meihong Yu; Haozhen Li; Quan Zhu; Ziqiang Wu; Zhao Wang; Zhengyan Tang
Journal:  Int J Gen Med       Date:  2022-03-24

Review 3.  Thrombotic complications in patients with cancer: Advances in pathogenesis, prevention, and treatment-A report from ICTHIC 2021.

Authors:  Anna Falanga; Benjamin Brenner; Alok A Khorana; Charles W Francis
Journal:  Res Pract Thromb Haemost       Date:  2022-07-01

Review 4.  Challenges of extended venous thromboembolism prophylaxis in medical and surgical patients.

Authors:  Maria Chiara Chindamo; Edison Ferreira Paiva; Plinio Resende do Carmo; Ana Thereza Cavalcanti Rocha; Marcos Arêas Marques
Journal:  J Vasc Bras       Date:  2022-06-27

5.  Measures of Care Coordination at Inpatient Psychiatric Facilities and the Medicare 30-Day All-Cause Readmission Rate.

Authors:  Ivy Benjenk; Morgan Shields; Jie Chen
Journal:  Psychiatr Serv       Date:  2020-08-25       Impact factor: 3.084

6.  Venous Thromboembolism (VTE) Incidence and VTE-Associated Survival among Olmsted County Residents of Local Nursing Homes.

Authors:  Tanya M Petterson; Carin Y Smith; Jane A Emerson; Kent R Bailey; Aneel A Ashrani; John A Heit; Cynthia L Leibson
Journal:  Thromb Haemost       Date:  2018-07-02       Impact factor: 5.249

7.  A novel risk assessment model for venous thromboembolism after major thoracic surgery: a Chinese single-center study.

Authors:  Bo Tian; Hui Li; Songping Cui; Chunfeng Song; Tong Li; Bin Hu
Journal:  J Thorac Dis       Date:  2019-05       Impact factor: 2.895

8.  Incidence of Venous Thromboembolism in a Racially Diverse Population of Oklahoma County, Oklahoma.

Authors:  Aaron M Wendelboe; Janis Campbell; Kai Ding; Dale W Bratzler; Michele G Beckman; Nimia L Reyes; Gary E Raskob
Journal:  Thromb Haemost       Date:  2021-01-10       Impact factor: 5.249

Review 9.  Current Opinion on the use of Direct Oral Anticoagulants for the Prophylaxis of Venous Thromboembolism among Medical Inpatients.

Authors:  Jane J Lee; Sahar Memar Montazerin; Fahimehalsadat Shojaei; Gerald Chi
Journal:  Ther Clin Risk Manag       Date:  2021-05-26       Impact factor: 2.423

10.  Post-discharge thrombosis and bleeding in medical patients: A novel risk score derived from ubiquitous biomarkers.

Authors:  Scott C Woller; Scott M Stevens; Masarret Fazili; James F Lloyd; Emily L Wilson; Gregory L Snow; Joseph R Bledsoe; Benjamin D Horne
Journal:  Res Pract Thromb Haemost       Date:  2021-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.